BrainsWay Receives Significant New Order for Deep TMS™ Systems

New York, March 25, 2024 - PRISM MarketView - Mental health company, BrainsWay Ltd. (Nasdaq: BWAY) has received an order for 18 of its Deep Transcranial Magnetic Stimulation (Deep TMS™) systems from Katie’s Way Plus. BrainsWay’s patented, clinically validated, Deep TMS system offers an in-office breakthrough treatment using flexible H-Coils embedded in a comfortable helmet to noninvasively activate targeted brain structures.

Katie’s Way Plus provides comprehensive mental health services tailored to the unique needs of active duty military members, veterans, and their families. The order brings Katie’s Way Plus’ network to an extensive 40 Deep TMS systems.

BrainsWay’s patented H-Coil design enables deeper and broader stimulation than traditional TMS coils, resulting in greater activation of neurons, less likelihood of targeting errors, and powerful efficacy.

Deep TMS is a clinically proven, noninvasive in-office brain stimulation treatment that uses magnetic fields to activate neural networks in the brain to improve symptoms of mental health and addiction conditions, including depression, anxiety, obsessive-compulsive disorder, and smoking addiction.

Since September 11, 2001, the prevalence of mental health conditions within the veteran community has increased, with diagnosed cases of major depressive disorder up by 32%, and doctor visits for the condition now account for nearly 10% of all military health network appointments.

In a study conducted across 27 states, it was found that the suicide rate among veterans is 50% higher than non-veterans.

BrainsWay is a global leader in advanced non invasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

BrainsWay Ltd. (Nasdaq: BWAY) is featured on PRISM Emerging Mental Health Index 

Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.

PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.

PRISM MarketView
info@prismmarketview.com
646-863-6341